YALE PHYLLIS R 4

What Happened
Phyllis R. Yale, a non-employee director of Bristol Myers Squibb (BMY), was granted 3,996.367 deferred share units on Feb 1, 2026. The filing records a notional price of $55.05 per share, for a reported aggregate value of $220,000. This was an award/award-equivalent (transaction code A) of a derivative security (deferred share units), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-01; SEC filing date: 2026-02-03 (filed within the standard 2-business-day window).
• Award: 3,996.367 Deferred Share Units; per-unit value shown $55.05; total reported value $220,000.
• Security type: Derivative (Deferred Share Units) that will convert into common stock upon settlement (see footnote).
• Footnotes: F1 — units convert to shares upon settlement; units become settleable when the director leaves the board or at a previously specified future date. F2 — includes deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Shares owned after transaction: Not specified in this filing.

Context
Deferred share units are a form of non-cash director compensation and represent a right to receive company stock in the future; they are not immediately tradable shares. Such awards reflect routine board compensation rather than an immediate market signal of insider buying or selling.